• Researcher Profile

    G. Mike Makrigiorgos, PhD

    G. Mike Makrigiorgos, PhD
    Associate Professor of Radiation Oncology, Harvard Medical School

    Office phone: 617-525-7122
    Fax: 617-582-6037
    Email: mmakrigiorgos@partners.org

    Preferred contact method: email

    Research Department

    Radiation Oncology

    Area of Research

    Technologies for novel Radiation Biophysics and Mutational Profiling of Tumors

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Jimmy Fund 615
    Boston, MA 02215


    Dr. Makrigiorgos received his PhD in medical physics from the University of Leeds, UK, in 1984 and his postdoctoral training in radiation biology from Harvard Medical School. Since 1990, he has been a member of the Physics Division of the Department of Radiation Therapy, Dana-Farber Brigham Cancer Center. He currently directs the biophysics radiation research effort and serves as the Chief of the Division of Medical Physics and Biophysics of the Department of Radiation Oncology. His laboratory develops technologies for DNA analysis and detection of cancer DNA biomarkers in blood, tumor tissue and bodily fluids.


    Technologies for novel Radiation Biophysics and Mutational Profiling of Tumors

    Medical Physics and Biophysics Research

    We are developing novel physics and biological approaches that utilize the combined powers of functional imaging, image-guided radiation therapy, nano-technology and molecularly targeted biological agents, to improve and personalize cancer treatment.

    Molecular Biophysics Research

    We are developing new technologies for molecular profiling of human tumors. In particular, we have devised novel methods for detecting DNA mutations and methylation in clinical samples. We are also using these new technologies to improve detection of cancer DNA biomarkers in human blood, for the purpose of early detection of cancer or monitoring of the progress of radio/chemotherapy. For example, we developed new whole-genome amplification methodologies that enhance identification of plasma-circulating DNA of tumor origin. Ongoing clinical studies are evaluating these biomarkers in radiation oncology patients.

    Select Publications

    • Wang G, Brennan C, Rook M, Wolfe J, Leo C, Chin L, Pan H, Liu W, Price B, Makrigiorgos GM. Balanced-PCR amplification allows unbiased identification of genomic copy changes in minute cell and tissue samples. Nucleic Acids Res 2004;32:e76.
    • Wang G, Maher E, Brennan C, Leo C, Chin L, Rook M, Wolfe J, Kaur M, Zhu P, Makrigiorgos GM. DNA amplification method tolerant to sample degradation. Genome Res 2004;14:2357-66.
    • Liu W, Kaur M, Wang G, Zhu P, Zhang Y, Makrigiorgos GM. Inverse PCR-based RFLP scanning identifies low-level mutation signatures in human cells and tumors. Cancer Res 2004;64:2544-51.
    • Li J, Wang L, Mamon H, Kulke M, Berbeco R, and Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nature Medicine, 2008; 14: pp579 584
    • Cormack R, Suh W, DAmico A and Makrigiorgos GM. Biological In-Situ dose-painting for image-guided radiation therapy using drug-loaded implantable devices. International Journal for Radiation Oncology, Biology and Physics, 2009; 76, Issue 2, pp 615-623
    • Makrigiorgos GM, Chakrabarti S, Zhang Y and Price B. PCR-based amplification method retaining the quantitative difference between two complex genomes. Nature Biotechnology, 2002, 20:936-939.


    • Li, Jin, MD, PhD


    • Liu, Pingfang, PhD
    • Milbury, Coren, PhD
    • Song, Chen, MSc
View Physician Directory

Find a Clinical Trial

Support Cancer

Give Now